Loading…
Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey
Risk stratification continues to evolve in pulmonary arterial hypertension (PAH). Our aim was to further confirm the risk assessment strategy in our cohort and to determine the most reliable model. We enrolled incident patients with idiopathic PAH (IPAH), heritable, drug-induced, congenital heart di...
Saved in:
Published in: | Anatolian journal of cardiology 2019-06, Vol.21 (6), p.322-330 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 330 |
container_issue | 6 |
container_start_page | 322 |
container_title | Anatolian journal of cardiology |
container_volume | 21 |
creator | Yaylalı, Yalın Tolga Başarıcı, Ibrahim Kılıçkıran Avcı, Burçak Meriç, Murat Sinan, Ümit Yaşar Şenol, Hande Küçükoğlu, Mehmet Serdar Öngen, Zeki |
description | Risk stratification continues to evolve in pulmonary arterial hypertension (PAH). Our aim was to further confirm the risk assessment strategy in our cohort and to determine the most reliable model.
We enrolled incident patients with idiopathic PAH (IPAH), heritable, drug-induced, congenital heart disease (CHD), connective tissue diseases (CTD) subsets, and chronic thromboembolic pulmonary hypertension (CTEPH) from January 2008 to February 2018. Data from the baseline and subsequent follow-ups within 1 year of diagnosis were included. An abbreviated risk assessment strategy was applied using the following variables: functional class (FC), 6-minute walk distance (6 MWD), N-terminal pro-brain natriuretic peptide (NT-proBNP) or BNP, right atrial (RA) area, pericardial effusion, the mean RA pressure, cardiac index, and mixed venous oxygen saturation. Three different methods were applied to categorize patients.
A total of 189 subjects (46+-17 years, 23% male) were included. Sixty-one patients had died. The survival differed significantly between the risk groups both at diagnosis and during the follow-up. Patients with a low-risk profile had a better survival rate. An abbreviated risk assessment tool predicted mortality at early follow-up in the entire group and CHD, CTD subsets, and CTEPH, separately. An overall mortality among risk categories was significantly different according to each categorization method. The most reliable model comprised FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up.
The abbreviated risk assessment tool may be valid for the PAH subsets and CTEPH. Echocardiographic variables do matter. A model comprising FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up could be useful for better prognostication. |
doi_str_mv | 10.14744/AnatolJCardiol.2019.53498 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6683229</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2257691041</sourcerecordid><originalsourceid>FETCH-LOGICAL-p294t-7e7e61ba6bd2a6ef1b99671ddf88165478f5fe1dbc438b38e8444cee8753ecf73</originalsourceid><addsrcrecordid>eNpdkU9P3DAQxS0EAkT5CpVFL73skrEd2-FQCa0ofwRCQvQcOcmka3Ds1E6W7revq1LUcprRvN88vdEQcgLFEoQS4vTcmym4m5WJnQ1uyQqoliUXld4hhwxEtWBMwe5bL_kBOU7pqSgKUFwDyH1ywAEEUwwOSf9g0zM1KWFKA_qJGt_RNMeN3RhHQ09HM9k8T_TFTms6zm4I3sQtXW9HjBP6ZIM_o3ezm2ybOYwUf2Yl77RIraePc3zG7Qey1xuX8Pi1HpFvXy8eV1eL2_vL69X57WJklZgWChVKaIxsOmYk9tBUlVTQdb3WIEuhdF_2CF3TCq4brlELIVpErUqOba_4Efnyx3ecmwG734micfUY7ZBD18HY-n_F23X9PWxqKTVnrMoGn18NYvgxY5rqwaYWnTMew5xqxjjLb-CszOind-hTmKPP52WqVLKCQkCmPv6b6C3K3xfwXxlgkPU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2257691041</pqid></control><display><type>article</type><title>Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey</title><source>PubMed (Medline)</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>Yaylalı, Yalın Tolga ; Başarıcı, Ibrahim ; Kılıçkıran Avcı, Burçak ; Meriç, Murat ; Sinan, Ümit Yaşar ; Şenol, Hande ; Küçükoğlu, Mehmet Serdar ; Öngen, Zeki</creator><creatorcontrib>Yaylalı, Yalın Tolga ; Başarıcı, Ibrahim ; Kılıçkıran Avcı, Burçak ; Meriç, Murat ; Sinan, Ümit Yaşar ; Şenol, Hande ; Küçükoğlu, Mehmet Serdar ; Öngen, Zeki</creatorcontrib><description>Risk stratification continues to evolve in pulmonary arterial hypertension (PAH). Our aim was to further confirm the risk assessment strategy in our cohort and to determine the most reliable model.
We enrolled incident patients with idiopathic PAH (IPAH), heritable, drug-induced, congenital heart disease (CHD), connective tissue diseases (CTD) subsets, and chronic thromboembolic pulmonary hypertension (CTEPH) from January 2008 to February 2018. Data from the baseline and subsequent follow-ups within 1 year of diagnosis were included. An abbreviated risk assessment strategy was applied using the following variables: functional class (FC), 6-minute walk distance (6 MWD), N-terminal pro-brain natriuretic peptide (NT-proBNP) or BNP, right atrial (RA) area, pericardial effusion, the mean RA pressure, cardiac index, and mixed venous oxygen saturation. Three different methods were applied to categorize patients.
A total of 189 subjects (46+-17 years, 23% male) were included. Sixty-one patients had died. The survival differed significantly between the risk groups both at diagnosis and during the follow-up. Patients with a low-risk profile had a better survival rate. An abbreviated risk assessment tool predicted mortality at early follow-up in the entire group and CHD, CTD subsets, and CTEPH, separately. An overall mortality among risk categories was significantly different according to each categorization method. The most reliable model comprised FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up.
The abbreviated risk assessment tool may be valid for the PAH subsets and CTEPH. Echocardiographic variables do matter. A model comprising FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up could be useful for better prognostication.</description><identifier>ISSN: 2149-2263</identifier><identifier>EISSN: 2149-2271</identifier><identifier>DOI: 10.14744/AnatolJCardiol.2019.53498</identifier><identifier>PMID: 31142721</identifier><language>eng</language><publisher>Turkey: Kare Publishing</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Cardiology ; Cardiovascular disease ; Chronic Disease ; Cohort Studies ; Congenital diseases ; Connective Tissue Diseases - complications ; Echocardiography ; Female ; Follow-Up Studies ; Heart ; Heart Defects, Congenital - complications ; Humans ; Hypertension, Pulmonary - diagnostic imaging ; Hypertension, Pulmonary - etiology ; Hypertension, Pulmonary - mortality ; Male ; Medicine ; Middle Aged ; Mortality ; Original Investigation ; Pulmonary Embolism - complications ; Pulmonary hypertension ; Risk Assessment ; Survival Rate ; Thromboembolism ; Turkey ; Young Adult</subject><ispartof>Anatolian journal of cardiology, 2019-06, Vol.21 (6), p.322-330</ispartof><rights>2019. Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the associated terms available at http://www.anakarder.com/Copyright</rights><rights>Copyright: © 2019 Turkish Society of Cardiology 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2257691041/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2257691041?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31142721$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yaylalı, Yalın Tolga</creatorcontrib><creatorcontrib>Başarıcı, Ibrahim</creatorcontrib><creatorcontrib>Kılıçkıran Avcı, Burçak</creatorcontrib><creatorcontrib>Meriç, Murat</creatorcontrib><creatorcontrib>Sinan, Ümit Yaşar</creatorcontrib><creatorcontrib>Şenol, Hande</creatorcontrib><creatorcontrib>Küçükoğlu, Mehmet Serdar</creatorcontrib><creatorcontrib>Öngen, Zeki</creatorcontrib><title>Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey</title><title>Anatolian journal of cardiology</title><addtitle>Anatol J Cardiol</addtitle><description>Risk stratification continues to evolve in pulmonary arterial hypertension (PAH). Our aim was to further confirm the risk assessment strategy in our cohort and to determine the most reliable model.
We enrolled incident patients with idiopathic PAH (IPAH), heritable, drug-induced, congenital heart disease (CHD), connective tissue diseases (CTD) subsets, and chronic thromboembolic pulmonary hypertension (CTEPH) from January 2008 to February 2018. Data from the baseline and subsequent follow-ups within 1 year of diagnosis were included. An abbreviated risk assessment strategy was applied using the following variables: functional class (FC), 6-minute walk distance (6 MWD), N-terminal pro-brain natriuretic peptide (NT-proBNP) or BNP, right atrial (RA) area, pericardial effusion, the mean RA pressure, cardiac index, and mixed venous oxygen saturation. Three different methods were applied to categorize patients.
A total of 189 subjects (46+-17 years, 23% male) were included. Sixty-one patients had died. The survival differed significantly between the risk groups both at diagnosis and during the follow-up. Patients with a low-risk profile had a better survival rate. An abbreviated risk assessment tool predicted mortality at early follow-up in the entire group and CHD, CTD subsets, and CTEPH, separately. An overall mortality among risk categories was significantly different according to each categorization method. The most reliable model comprised FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up.
The abbreviated risk assessment tool may be valid for the PAH subsets and CTEPH. Echocardiographic variables do matter. A model comprising FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up could be useful for better prognostication.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cardiology</subject><subject>Cardiovascular disease</subject><subject>Chronic Disease</subject><subject>Cohort Studies</subject><subject>Congenital diseases</subject><subject>Connective Tissue Diseases - complications</subject><subject>Echocardiography</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Heart</subject><subject>Heart Defects, Congenital - complications</subject><subject>Humans</subject><subject>Hypertension, Pulmonary - diagnostic imaging</subject><subject>Hypertension, Pulmonary - etiology</subject><subject>Hypertension, Pulmonary - mortality</subject><subject>Male</subject><subject>Medicine</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Original Investigation</subject><subject>Pulmonary Embolism - complications</subject><subject>Pulmonary hypertension</subject><subject>Risk Assessment</subject><subject>Survival Rate</subject><subject>Thromboembolism</subject><subject>Turkey</subject><subject>Young Adult</subject><issn>2149-2263</issn><issn>2149-2271</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkU9P3DAQxS0EAkT5CpVFL73skrEd2-FQCa0ofwRCQvQcOcmka3Ds1E6W7revq1LUcprRvN88vdEQcgLFEoQS4vTcmym4m5WJnQ1uyQqoliUXld4hhwxEtWBMwe5bL_kBOU7pqSgKUFwDyH1ywAEEUwwOSf9g0zM1KWFKA_qJGt_RNMeN3RhHQ09HM9k8T_TFTms6zm4I3sQtXW9HjBP6ZIM_o3ezm2ybOYwUf2Yl77RIraePc3zG7Qey1xuX8Pi1HpFvXy8eV1eL2_vL69X57WJklZgWChVKaIxsOmYk9tBUlVTQdb3WIEuhdF_2CF3TCq4brlELIVpErUqOba_4Efnyx3ecmwG734micfUY7ZBD18HY-n_F23X9PWxqKTVnrMoGn18NYvgxY5rqwaYWnTMew5xqxjjLb-CszOind-hTmKPP52WqVLKCQkCmPv6b6C3K3xfwXxlgkPU</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>Yaylalı, Yalın Tolga</creator><creator>Başarıcı, Ibrahim</creator><creator>Kılıçkıran Avcı, Burçak</creator><creator>Meriç, Murat</creator><creator>Sinan, Ümit Yaşar</creator><creator>Şenol, Hande</creator><creator>Küçükoğlu, Mehmet Serdar</creator><creator>Öngen, Zeki</creator><general>Kare Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EDSIH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190601</creationdate><title>Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey</title><author>Yaylalı, Yalın Tolga ; Başarıcı, Ibrahim ; Kılıçkıran Avcı, Burçak ; Meriç, Murat ; Sinan, Ümit Yaşar ; Şenol, Hande ; Küçükoğlu, Mehmet Serdar ; Öngen, Zeki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p294t-7e7e61ba6bd2a6ef1b99671ddf88165478f5fe1dbc438b38e8444cee8753ecf73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cardiology</topic><topic>Cardiovascular disease</topic><topic>Chronic Disease</topic><topic>Cohort Studies</topic><topic>Congenital diseases</topic><topic>Connective Tissue Diseases - complications</topic><topic>Echocardiography</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Heart</topic><topic>Heart Defects, Congenital - complications</topic><topic>Humans</topic><topic>Hypertension, Pulmonary - diagnostic imaging</topic><topic>Hypertension, Pulmonary - etiology</topic><topic>Hypertension, Pulmonary - mortality</topic><topic>Male</topic><topic>Medicine</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Original Investigation</topic><topic>Pulmonary Embolism - complications</topic><topic>Pulmonary hypertension</topic><topic>Risk Assessment</topic><topic>Survival Rate</topic><topic>Thromboembolism</topic><topic>Turkey</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yaylalı, Yalın Tolga</creatorcontrib><creatorcontrib>Başarıcı, Ibrahim</creatorcontrib><creatorcontrib>Kılıçkıran Avcı, Burçak</creatorcontrib><creatorcontrib>Meriç, Murat</creatorcontrib><creatorcontrib>Sinan, Ümit Yaşar</creatorcontrib><creatorcontrib>Şenol, Hande</creatorcontrib><creatorcontrib>Küçükoğlu, Mehmet Serdar</creatorcontrib><creatorcontrib>Öngen, Zeki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Turkey Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Anatolian journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yaylalı, Yalın Tolga</au><au>Başarıcı, Ibrahim</au><au>Kılıçkıran Avcı, Burçak</au><au>Meriç, Murat</au><au>Sinan, Ümit Yaşar</au><au>Şenol, Hande</au><au>Küçükoğlu, Mehmet Serdar</au><au>Öngen, Zeki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey</atitle><jtitle>Anatolian journal of cardiology</jtitle><addtitle>Anatol J Cardiol</addtitle><date>2019-06-01</date><risdate>2019</risdate><volume>21</volume><issue>6</issue><spage>322</spage><epage>330</epage><pages>322-330</pages><issn>2149-2263</issn><eissn>2149-2271</eissn><abstract>Risk stratification continues to evolve in pulmonary arterial hypertension (PAH). Our aim was to further confirm the risk assessment strategy in our cohort and to determine the most reliable model.
We enrolled incident patients with idiopathic PAH (IPAH), heritable, drug-induced, congenital heart disease (CHD), connective tissue diseases (CTD) subsets, and chronic thromboembolic pulmonary hypertension (CTEPH) from January 2008 to February 2018. Data from the baseline and subsequent follow-ups within 1 year of diagnosis were included. An abbreviated risk assessment strategy was applied using the following variables: functional class (FC), 6-minute walk distance (6 MWD), N-terminal pro-brain natriuretic peptide (NT-proBNP) or BNP, right atrial (RA) area, pericardial effusion, the mean RA pressure, cardiac index, and mixed venous oxygen saturation. Three different methods were applied to categorize patients.
A total of 189 subjects (46+-17 years, 23% male) were included. Sixty-one patients had died. The survival differed significantly between the risk groups both at diagnosis and during the follow-up. Patients with a low-risk profile had a better survival rate. An abbreviated risk assessment tool predicted mortality at early follow-up in the entire group and CHD, CTD subsets, and CTEPH, separately. An overall mortality among risk categories was significantly different according to each categorization method. The most reliable model comprised FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up.
The abbreviated risk assessment tool may be valid for the PAH subsets and CTEPH. Echocardiographic variables do matter. A model comprising FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up could be useful for better prognostication.</abstract><cop>Turkey</cop><pub>Kare Publishing</pub><pmid>31142721</pmid><doi>10.14744/AnatolJCardiol.2019.53498</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2149-2263 |
ispartof | Anatolian journal of cardiology, 2019-06, Vol.21 (6), p.322-330 |
issn | 2149-2263 2149-2271 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6683229 |
source | PubMed (Medline); Publicly Available Content Database (Proquest) (PQ_SDU_P3) |
subjects | Adolescent Adult Aged Aged, 80 and over Cardiology Cardiovascular disease Chronic Disease Cohort Studies Congenital diseases Connective Tissue Diseases - complications Echocardiography Female Follow-Up Studies Heart Heart Defects, Congenital - complications Humans Hypertension, Pulmonary - diagnostic imaging Hypertension, Pulmonary - etiology Hypertension, Pulmonary - mortality Male Medicine Middle Aged Mortality Original Investigation Pulmonary Embolism - complications Pulmonary hypertension Risk Assessment Survival Rate Thromboembolism Turkey Young Adult |
title | Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T16%3A20%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20assessment%20and%20survival%20of%20patients%20with%20pulmonary%20hypertension:%20Multicenter%20experience%20in%20Turkey&rft.jtitle=Anatolian%20journal%20of%20cardiology&rft.au=Yaylal%C4%B1,%20Yal%C4%B1n%20Tolga&rft.date=2019-06-01&rft.volume=21&rft.issue=6&rft.spage=322&rft.epage=330&rft.pages=322-330&rft.issn=2149-2263&rft.eissn=2149-2271&rft_id=info:doi/10.14744/AnatolJCardiol.2019.53498&rft_dat=%3Cproquest_pubme%3E2257691041%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p294t-7e7e61ba6bd2a6ef1b99671ddf88165478f5fe1dbc438b38e8444cee8753ecf73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2257691041&rft_id=info:pmid/31142721&rfr_iscdi=true |